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Reply to the Editor:
Thank you for the invitation to respond to
Dr Casati and colleagues’ letter. We used
an in vitro bleeding time test (Platelet
Function Analyzer [PFA]-100) to evaluate
platelet function perioperatively at 7 differ-
ent observation times. Only one of these
observations was performed during cardio-
pulmonary bypass with hemodiluted pa-
tients. Fibrinolytic activity can indirectly
be measured, evaluating the balance be-
tween the promoter of fibrinolysis (tissue-
type plasminogen activator) and its inhibi-
tor (plasminogen activator inhibitor 1). In
our study1 we observed that tissue-type
plasminogen activator levels are not in-
creased, whereas plasminogen activator in-
hibitor 1 and D-dimer levels are modestly
increased after off-pump coronary artery
bypass (OPCAB) surgery. These data
would suggest that fibrinolysis is not par-
ticularly activated during OPCAB surgery.
Dr Casati states that an antifibrinolytic
agent should be used in patients undergo-
ing OPCAB surgery because he has previ-
ously demonstrated2 a significant reduction
of postoperative bleeding in patients under-
going OPCAB treated with tranexamic acid
(25 patients) compared with patients under-
going OPCAB treated with placebo (25
patients). In their study Casati and col-
leagues2 were not able to show a significant
difference in blood product transfusion be-
tween the groups. Moreover, hemoglobin
and hematocrit values reported up to 24
hours postoperatively were not influenced
by tranexamic acid administration. As we
remarked in our article, recent studies with
angiographic control have shown a worse
graft patency in patients operated on by
means of the OPCAB technique compared
with those undergoing the on-pump tech-
nique. Inaccurate anastomosis rather than a
procoagulative state is probably the main
cause of these results; nevertheless, this has
not been proved. Although numerous in-
vestigators have documented profound
short-term and midterm coagulative-
fibrinolytic and inflammatory alterations in
patients undergoing coronary artery bypass
grafting surgery, there are no clinical stud-
ies that evaluated prospectively and on an
appropriate number of patients the value of
prothrombotic and proinflammatory mark-
ers in predicting early graft occlusion. Ex-
isting studies are small and produced con-
flicting results: Poston and associates3
reported that thrombelastography and
whole blood aggregometry do not predict
graft occlusion; however, in another study
the same authors showed a reduction in
platelet sensitivity to aspirin by means of
both thrombelastography and aggregom-
etry in patients with early graft failure.4
Karski and coworkers5 have recently dem-
onstrated that tranexamic acid administra-
tion does not worsen early saphenous graft
patency in patients receiving on-pump cor-
onary artery bypass grafting. However, our
results show that in the first 24 hours after
the operation, patients undergoing on-
pump operations and OPCAB have a dif-
ferent activation of the coagulation and fi-
brinolytic systems. Consequently, what is
safe for patients undergoing on-pump op-
erations might not be safe for those under-
going OPCAB. The reason why we operate
on patients with coronary artery disease is
to improve their long-term outcome while
trying to minimize their perioperative risk.
Considering that postoperative bleeding is
not a serious complication after OPCAB
surgery, we agree with Dr Casati’s final
remarks: “Further randomized studies, en-
rolling larger numbers of patients, are
needed to confirm the antiinflammatory ef-
fects of TA and to rule out the potential risk
of thrombotic complications.”2
Domenico Paparella, MD
Antonella Galeone, MD
Giuseppe Scrascia, MD
Division of Cardiac Surgery
University of Bari
Piazza Giulio Cesare 11
Bari 70100
Italy
E-mail: paparella@tin.it
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A new surgical paradigm: Hybrid
open and endovascular repair of the
ascending aorta and aortic arch for
acute type A dissection
To the Editor:
I read with interest the editorial by
Dobrilovic and Elefteriades1 reflecting on
the potential future application of simulta-
neous hybrid endoluminal graft repair of
the descending thoracic aorta after tradi-
tional open surgical repair of the ascending
aorta and aortic arch for acute type A aortic
dissection, as discussed in the article by
Uchida and associates.2
Although the results reported by Uchida
and associates2 are noteworthy, stabilizing
the true lumen in the descending thoracic
aorta with an endoluminal graft after total
aortic arch replacement may not be the final,
or best, approach for acute type A aortic
dissection. The current surgical paradigm is
Letters to the Editor
734 The Journal of Thoracic and Cardiovascular Surgery ● September 2006
to treat the ascending aortic and arch pa-
thology in the standard open surgical fash-
ion and follow the progression of the de-
scending thoracic aorta. As Dobrilovic and
Elefteriades1 expertly point out, expansion
of the descending thoracic aorta after acute
type A dissection may be a slow process.
There may, however, be additional reasons
to consider simultaneous hybrid repair in
this situation.
Total arch replacement involves the use
of deep hypothermic circulatory arrest
(DHCA). The increased risks associated
with this technique have been well docu-
mented, and eliminating DHCA for the
treatment of acute Type A aortic dissec-
tions would potentially make this a safer
and better tolerated procedure. Another al-
ternative hybrid approach would be to re-
pair the entry point tear in the ascending
aorta with standard open surgical tech-
niques (interposition graft or ascending
conduit) and simultaneously bypass the
great vessels with grafts off the newly com-
pleted ascending aortic graft. Simultaneous
deployment of an endoluminal graft in an
antegrade fashion through the ascending
graft, across the aortic arch, and into the
proximal descending thoracic aorta would
accomplish a total arch reconstruction
without the need for DHCA.3 This ap-
proach maximizes the advantages of
endovascular technologies by making a
complex procedure less invasive while sta-
bilizing the true lumen of the descending
thoracic aorta. We have shown that stabi-
lizing the true lumen in the descending
thoracic aorta is an active process that in
time leads to progressive expansion of the
true lumen and continued thrombosis of the
false lumen.4 In addition to potentially pre-
venting future complications and need for
reoperation, stabilization of the true lumen
and continued active true lumen expansion
after thoracic endografting can potentially
improve distal organ perfusion.
Hybrid approaches to complex aortic
pathologies may allow us to offer surgical
repair to patients with acute type A aortic
dissection who might not otherwise tolerate
DHCA. The less invasive advantages of
simultaneous arch exclusion with an endolu-
minal graft after great vessel transposition
could accelerate patient recovery and provide
the added potential advantage of distal true
lumen stabilization. I therefore believe that the
surgical paradigm may be shifting toward
hybrid approaches, not away from them.
Grayson H. Wheatley III, MD
Arizona Heart Institute
Phoenix, Ariz
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Reply to the Editor:
We appreciate the thoughtful commentary
from Dr Wheatley. We are aware of the
imaginative work being done in catheter-
based treatment of aortic diseases at the
Arizona Heart Institute.
There are certainly many clever ways to
“manipulate” the anatomy of the aortic
arch to make stent therapy feasible, and we
applaud the exploration of these tech-
niques. We disagree, however, with the
undercurrent of fear of deep hypothermic
circulatory arrest (DHCA) manifest in Dr
Wheatley’s letter.
DHCA is a proven modality in aortic sur-
gery, with a vast clinical experience demon-
strating its clinical utility and safety.1-4 At
our own institution, Dr Arjet Gega has just
completed (for upcoming submission) a re-
view of 400 patients operated on under
“straight” DHCA, without any adjunctive
retrograde or antegrade cerebral perfusion.
This experience included all comers: as-
cending, arch, descending, and thoracoab-
dominal; elective and emergency; and rup-
tured and nonruptured. Overall mortality
was 6.5%, stroke rate was 4.9%, and reex-
ploration for bleeding was 3.9%. Cerebral
protection was excellent, with most strokes
embolic in origin. The supposed bleeding
diathesis of DHCA is simply not a prob-
lem. It is not uncommon for us to find the
morning’s DHCA patient extubated, vi-
brantly conversant, and having a light sup-
per by the time of evening rounds. DHCA
need not be feared. At our institution we
marvel at the protective abilities of this
technique, and we are pleased to call upon
them at every opportunity.
Current results for surgery under DHCA
at many expert centers worldwide sets a
standard that will be hard to exceed with
clever extra-anatomic and catheter based
modalities. In fact, it remains to be shown
in careful analysis of large clinical series
that the alternative modalities can even come
close to meeting the excellent results of tra-
ditional, direct arch surgery under DHCA.
John A. Elefteriades, MD
Nikola Dobrilovic, MD
Arjet Gega, MD
Department of Cardiothoracic Surgery
Yale University School of Medicine
New Haven, Conn
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When less is more: Go slowly when
repopulating a decellularized valve
in vivo!
To the Editor:
We read with interest the recent article by
Juthier and colleagues1 describing the ef-
fects of granulocyte colony-stimulating
factor (GCSF) on decellularized xenogenic
heart valves implanted in systemic circula-
tion in sheep. The hypothesis was tested
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